Blog

Dec 7, 2024, 11:11

Important factors associated with risk of developing melanoma in Rhode Island by Oliver Wisco

Wafik S. El-Deiry shared a post on X:

“Great presentation by Dr. Oliver Wisco at the Legorreta Cancer Center Cancer Therapeutics Program meeting today.

His research is uncovering important factors associated with risk of developing melanoma in Rhode Island, including distance traveled to tanning salons.”

The Cancer Therapeutics Program brings together clinical investigators who work together with basic and translational scientists to advance promising therapeutic options to patients in clinical trials. Program meetings are held every two weeks throughout the year.

There is a robust portfolio of early phase clinical trials led by investigators through the Brown University Oncology Group (BrUOG), Brown University Health Cancer Institute and Women’s and Infants Hospital. The Program has depth of expertise in disease-based adult and pediatric oncology, pathology, and clinical investigations. The early phase experimental therapeutics effort has a strong focus on cell death pathways and immunotherapy.

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.